secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-07-21T11:07:31+00:00
Accession:  0001437749-26-023916
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals appoints Dr. R. Todd Plott to Board of Directors
---------------------------------------------------------------------

- Board size increased to six members; Dr. Plott appointed effective July 20, 2026 until 2026 annual meeting.
- Dr. Plott is a board-certified dermatologist with 30+ years experience and former FDA advisory committee member.
- He will receive standard non-employee director compensation and indemnification agreement.
- Appointment supports advancement of PH-762 for squamous cell carcinoma, per CEO Robert Bitterman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926023916/0001437749-26-023916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926023916/phio20260717_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-023916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer